Nano-mupirocin: enabling the parenteral activity of mupirocin
暂无分享,去创建一个
Amiram Goldblum | Yechezkel Barenholz | Ahuva Cern | A. Goldblum | Y. Barenholz | Y. Xiong | Erez Koren | Ayelet Michael-Gayego | Yaelle Bavli | Erez Koren | Allon E. Moses | Yan Q. Xiong | A. Moses | Yaelle Bavli | Ahuva Cern | A. Michael-Gayego
[1] Yechezkel Barenholz,et al. Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis. , 2008, Arthritis and rheumatism.
[2] K. Bayles,et al. Impact of vancomycin on sarA-mediated biofilm formation: role in persistent endovascular infections due to methicillin-resistant Staphylococcus aureus. , 2014, The Journal of infectious diseases.
[3] Alexander Golbraikh,et al. Quantitative structure-property relationship modeling of remote liposome loading of drugs. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[4] E. Azzopardi,et al. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. , 2013, The Journal of antimicrobial chemotherapy.
[5] V. Nizet,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[6] Yechezkel Barenholz,et al. Liposome application: problems and prospects , 2001 .
[7] S. Clerc,et al. Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. , 1995, Biochimica et biophysica acta.
[9] J. Hughes,et al. Interaction of pseudomonic acid A with Escherichia coli B isoleucyl-tRNA synthetase. , 1980, The Biochemical journal.
[10] Y. Barenholz. Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[11] N. Düzgüneş,et al. Liposome-encapsulated antibiotics. , 2005, Methods in Enzymology.
[12] A. Bayer,et al. Comparative Efficacies of Liposomal Amikacin (MiKasome) plus Oxacillin versus Conventional Amikacin plus Oxacillin in Experimental Endocarditis Induced by Staphylococcus aureus: Microbiological and Echocardiographic Analyses , 1999, Antimicrobial Agents and Chemotherapy.
[13] Yechezkel Barenholz,et al. Relevancy of Drug Loading to Liposomal Formulation Therapeutic Efficacy , 2003, Journal of liposome research.
[14] A. Goldblum,et al. Effect of solubilizing agents on mupirocin loading into and release from PEGylated nanoliposomes. , 2014, Journal of pharmaceutical sciences.
[15] R. Schiffelers,et al. In vivo synergistic interaction of liposome-coencapsulated gentamicin and ceftazidime. , 2001, The Journal of pharmacology and experimental therapeutics.
[16] K A Pappa,et al. The clinical development of mupirocin. , 1990, Journal of the American Academy of Dermatology.
[17] Yechezkel Barenholz,et al. Fabrication Principles and Their Contribution to the Superior In Vivo Therapeutic Efficacy of Nano-Liposomes Remote Loaded with Glucocorticoids , 2011, PloS one.
[18] Amiram Goldblum,et al. Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[19] Y. Barenholz,et al. Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies. , 1989, Biochimica et biophysica acta.
[20] Y. Barenholz,et al. Optimization and upscaling of doxorubicin-containing liposomes for clinical use. , 1990, Journal of pharmaceutical sciences.
[21] Amiram Goldblum,et al. Computer-aided design of liposomal drugs: In silico prediction and experimental validation of drug candidates for liposomal remote loading. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[22] S. Al-suwayeh,et al. Treatment of experimental osteomyelitis by liposomal antibiotics. , 2004, The Journal of antimicrobial chemotherapy.
[23] R. Pandey,et al. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. , 2002, International journal of antimicrobial agents.
[24] Jing Wang,et al. Polymyxin E sulfate-loaded liposome for intravenous use: preparation, lyophilization, and toxicity assessment in vivo. , 2009, PDA journal of pharmaceutical science and technology.
[25] K. Barrow,et al. Pseudomonic Acid: an Antibiotic produced by Pseudomonas fluorescens , 1971, Nature.
[26] R. Boon,et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use , 1985, Antimicrobial Agents and Chemotherapy.